Prof Yu Sunakawa speaks to ecancer in an online interview for the virtual ESMO GI 2020 meeting.

He explains the rationale behind the DELIVER trial, which is a large observational/translational study investigating the efficacy of nivolumab treatment in gastric cancer.

Prof Sunakawa outlines the design of this study, which incorporates real-world data to also identify novel biomarkers in this patient population.

He discusses the encouraging results, and the main conclusions of this study.